The unfolded protein response (UPR) is an ancient cellular pathway that detects and alleviates protein-folding stresses. The UPR components X-box binding protein 1 (XBP1) and inositol-requiring enzyme 1a (IRE1a) promote type I interferon (IFN) responses. We found that Xbp1-deficient mouse embryonic fibroblasts and macrophages had impaired antiviral resistance. However, this was not because of a defect in type I IFN responses but rather an inability of Xbp1-deficient cells to undergo viral-induced apoptosis. The ability to undergo apoptosis limited infection in wild-type cells. Xbp1-deficient cells were generally resistant to the intrinsic pathway of apoptosis through an indirect mechanism involving activation of the nuclease IRE1a. We observed an IRE1a-dependent reduction in the abundance of the proapoptotic microRNA miR-125a and a corresponding increase in the amounts of the members of the antiapoptotic Bcl-2 family. The activation of IRE1a by the hepatitis C virus (HCV) protein NS4B in XBP1-proficient cells also conferred apoptosis resistance and promoted viral replication. Furthermore, we found evidence of IRE1a activation and decreased miR-125a abundance in liver biopsies from patients infected with HCV compared to those in the livers of healthy controls. Our results reveal a prosurvival role for IRE1a in virally infected cells and suggest a possible target for IFN-independent antiviral therapy.
INTRODUCTION
Great advances have been made in our understanding of the molecular definitions of pattern recognition receptors (PRRs) and the pathogenassociated molecular patterns (PAMPs) that cells use to distinguish viruses from self (1, 2) . PRR engagement results in the transcription of the genes that encode the type I interferons (IFNs) IFN-a and IFN-b, which bind to the IFN-a/b receptor to induce the expression of hundreds of IFN-stimulated genes (ISGs). ISGs act in concert to block further viral replication and spread, as well as to support the activation of adaptive antiviral immunity (3) . However, many viruses have evolved evasion mechanisms to limit PRR recognition and signal transduction, and PRR-independent mechanisms for innate sensing of viral infections remain unclear.
Endoplasmic reticulum (ER) stress occurs during infection by various viruses, presumably due to the overwhelming synthesis of viral proteins (4) . The unfolded protein response (UPR) is a ubiquitous cellular pathway to detect and alleviate ER stress. The UPR is initiated by three sensors that reside within the ER: protein kinase receptor-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1) (5-7). IRE1, a highly conserved UPR sensor, oligomerizes and autophosphorylates in response to ER stress, which activates its cytosolic ribonuclease (RNase) domain and initiates a nonconventional mRNA splicing reaction of Xbp1 mRNA (8) . Once processed, the spliced Xbp1 mRNA encodes a transcription factor, which controls the expression of target genes. IRE1a targets other specific mRNAs, leading to their degradation in a process termed regulated IRE1-dependent decay (RIDD) (9, 10) . ER stress synergistically enhances cytokine and IFN responses to PRR engagement through IRE1a and X-box binding protein 1 (XBP1) (11) (12) (13) . Specific activation of IRE1a also occurs during innate immune recognition of PAMPs by Toll-like receptors (TLRs) (11) . In this setting, XBP1 promotes the production of inflammatory cytokines and IFN-b. Moreover, IRE1a generates ligands for RIG-I-like receptors (RLRs) during the UPR (14) , which are degraded by SKIV2L RNA exosomes to prevent inappropriate activation of type I IFN responses (15) . These observations prompted us to investigate the possible role of XBP1 in innate immune responses to viral infections, with the hypothesis that XBP1 could promote IFN-mediated viral resistance.
Here, we describe an unexpected role for XBP1 in antiviral resistance, not through enhancement of the IFN response but rather by modulating susceptibility to host cell apoptosis. Xbp1-deficient cells were resistant to apoptosis during infection with vesicular stomatitis virus (VSV) and herpes simplex virus (HSV), and failure to undergo cell death resulted in increased viral replication. Xbp1 deficiency results in activation of its upstream enzyme IRE1a, which degrades specific cytosolic RNA targets (16, 17) . We found that apoptosis resistance in the Xbp1-deficient cells required IRE1a and its degradation of microRNA (miRNA), miR-125a. Notably, the hepatitis C virus (HCV) nonstructural protein 4B (NS4B), which stimulates IRE1a activation (18) , promoted the survival of infected cells and viral replication. Moreover, liver biopsies from patients infected with HCV showed IRE1a activation and reduced miR-125a abundance compared to healthy controls. These findings highlight the role of UPR effectors in regulating IFN-independent mechanisms of innate antiviral resistance through the induction of apoptosis to limit viral infection.
RESULTS

Xbp1 deficiency impairs control of viral infection
To determine the effect of Xbp1 deficiency on host defense against viral replication, we infected Xbp1 −/− mouse embryonic fibroblasts (MEFs) with an RNA virus, VSV, and a DNA virus, HSV. XBP1 deficiency was achieved through an insertion of the neomycin resistance gene into parts of exons 1 and 2, as well as the intervening intron (19) . This insertion still enables Xbp1 mRNA splicing but results in a frameshift of the remaining amino acids to prevent protein production. Compared to wild-type (WT) MEFs, VSV replication was enhanced in Xbp1 −/− MEFs as determined by measuring VSV-G-green fluorescent protein (GFP) relative abundance by flow cytometry (Fig. 1, A and B) and by plaque assays of released virus from MEF culture medium (Fig. 1C) . Similarly, Xbp1 −/− MEFs also supported increased replication of HSV-1-GFP as indicated by measurement of GFP abundance (Fig. 1, D and E) and viral titer in the supernatant (Fig. 1F) .
To determine whether the impaired viral control in Xbp1 −/− MEFs resulted from deficient IFN responses, we measured the expression of genes encoding type I IFNs and of an ISG, Mx1, in MEFs infected with VSV. Unexpectedly, we observed enhanced induction of Ifna4 and Ifnb1 in Xbp1 −/− MEFs infected with VSV compared to WT MEFs ( fig. S1, A and B) . Induction of Mx1 also increased in Xbp1 −/− MEFs ( fig. S1C ). Moreover, Xbp1
−/− MEFs were not impaired in IFN responsiveness because pretreatment with IFN-b prevented VSV replication in Xbp1 −/− MEFs ( fig. S1D ). In contrast and consistent with previous reports (12, 13) , the Xbp1-deficient MEF response to transfection with polyinosinic:polycytidylic acid [poly(I:C)] [an MDA5 (melanoma differentiation-associated protein 5) agonist] was impaired ( fig. S1E ), suggesting that the enhanced IFN response to VSV was specific to replicating virus. Together, these findings suggest that Xbp1 contributes to protective antiviral responses independently of type I IFNs.
Xbp1 deficiency confers resistance to virus-triggered cell death Viral infection often culminates in the death of infected host cells. To determine whether the phenotype we observed in the Xbp1-deficient MEFs was due to a difference in the death of infected cells, we evaluated cell death and the abundance of virally encoded GFP after infection. During VSV infection, we found that most of the WT cells (~85%) were dead 24 hours after infection. In contrast, most Xbp1 −/− MEFs (~74%) were resistant to cell death and accumulated higher amounts of viral protein as determined by measurement of GFP abundance (Fig. 2, A  and B) . Similarly, whereas a large proportion of HSV-infected WT cells underwent cell death, infected Xbp1 −/− MEFs were resistant to death (Fig.  2, C and D) . To determine whether acute ablation of Xbp1 expression Twenty-four hours later, the extent of infection was determined by measuring the relative abundance of GFP by flow cytometry. Data are from one experiment representative of three independent experiments (A and D). The mean fluorescence intensity (MFI) of GFP in the indicated cells was then determined. Data are means ± SD of three independent experiments (B and E). Viral titers in the cell culture medium were measured by plaque assay at 48 (C) and 72 (F) hours after infection. PFU, plaque-forming units. Data are means ± SD of three independent experiments (C and F). *P < 0.05; ***P < 0.001 compared to WT, unpaired t test. (20) . Xbp1D BMDMs were resistant to death during VSV infection (Fig. 2, E and F, and fig. S2D ), indicating that Xbp1 genetic deficiency results in protection from cell death in fibroblasts and macrophages. These results suggest that there should not be an Xbp1-dependent antiviral phenotype against viruses that do not trigger the death of infected cells. We found that infection with a VSV-G pseudotyped lentivirus encoding GFP did not result in host cell death ( fig. S3A ). In this case, we did not observe enhanced production of virally encoded GFP in Xbp1 −/− MEFs ( fig. S3 , A and B). These findings suggest that impaired control of VSV and HSV infection by Xbp1 −/− MEFs was directly related to their resistance to cell death.
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Apoptosis limits the replication of VSV and HSV
The end point of cell death can result from numerous upstream signaling pathways. VSV infection induces apoptotic cell death in Jurkat cells (21) and MCF-7 breast adenocarcinoma cells (22) . WT MEFs infected with VSV demonstrated active caspase-3 ( Fig. 3A) , indicating apoptotic cell death in these cells. In contrast, Xbp1 −/− MEFs failed to activate caspase-3 during VSV infection (Fig. 3A) . Similarly, HSV-infected WT MEFs contained active caspase-3, and Xbp1
−/−
MEFs were resistant to the activation of this apoptotic effector (Fig.  3B ). These findings were not limited to MEFs because the activation of caspase-3 and caspase-7 also occurred in VSV-infected BMDMs and Xbp1D BMDMs were resistant to VSV-induced caspase-3 activation (Fig. 3C) .
Some viruses induce apoptosis as a means of viral transmission and avoidance of the immune system (23) . In other cases, apoptosis is beneficial for the host and limits viral replication. We observed decreased abundance of virally encoded GFP in the population of dead cells during HSV infection of WT MEFs (Fig. 2C) , suggesting that apoptosis may limit viral replication. To test this hypothesis, we added a caspase inhibitor, carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD), to infected cells. We found that zVAD prevented the death of VSV-infected MEFs (Fig. 3D ) and led to the increased abundance of virally encoded GFP (Fig. 3, D and E) , phenocopying the result obtained from experiments with Xbp1 −/− MEFs. Similarly, inhibition of apoptosis with zVAD increased the abundance of virally encoded GFP in HSV-infected MEFs, to an extent similar to that attained in Xbp1 −/− MEFs (Fig. 3F ). In addition, overproduction of the antiapoptotic protein BCL2 limited the death of VSV-infected cells and led to the increased abundance of virally encoded GFP ( fig.  S3C ). Together, these findings suggest that Xbp1-deficient cells are resistant to virus-induced apoptosis and that apoptosis directly limits viral replication. WT Xbp1 Resistance to virally induced apoptosis in Xpb1 −/− cells is independent of Beclin 1 and CHOP ER stress is associated with autophagy, which regulates cell survival (24) . In particular, XBP1 promotes transcription of the gene encoding the autophagy component, Beclin 1 (25) . Consistent with these data, we found decreased Beclin 1 in Xbp1-deficient cells ( fig. S4A ). However, knockdown of Beclin 1 with Beclin 1-specific siRNA did not affect VSV infection or the induction of cell death in either WT or Xbp1-deficient MEFs ( fig. S4B ). Our finding that Xbp1-deficient cells were resistant to VSV-and HSV-induced apoptosis suggests the possibility that apoptosis during viral infection may directly result from XBP1-mediated transcriptional activity. During ER stress, XBP1 partially contributes to the production of the apoptosis mediator CHOP (C/EBP homologous protein) (26) , an induction process that may play a role in virus-induced apoptosis. (27) and HSV (28, 29) .
Xbp1-deficient cells are resistant to the intrinsic pathway of apoptosis Because we did not find evidence for XBP1-mediated transcriptional activity in promoting apoptosis during infection, we hypothesized that Xbp1-deficient cells may be inherently resistant to apoptosis in general. We therefore treated Xbp1 −/− MEFs with a panel of apoptosis-inducing stimuli. Staurosporine and gliotoxin stimulate the intrinsic or mitochondrial pathway of apoptosis (30) (31) (32) (33) , whereas ligation of the tumor necrosis factor (TNF) and Fas receptors initiates the extrinsic apoptotic pathway (34) . Xbp1 −/− MEFs were specifically resistant to stimuli that induced the intrinsic pathway of apoptosis, both as demonstrated by increased viability (Fig. 4A ) and impaired caspase-3 activation (Fig.  4B) . Consistent with previous studies demonstrating a protective role of Xbp1 during ER stress (26, (35) (36) (37) , Xbp1 −/− MEFs were slightly more susceptible to death induced by tunicamycin (Fig. 4A ). In contrast, there was no difference between WT and Xbp1 −/− MEFs in necrotic death induced by a high concentration of cycloheximide (Fig. 4A) . These findings were further verified in experiments with Xbp1D BMDMs, which demonstrated resistance to staurosporine and the selective Bcl-2 inhibitor ABT-737 (38) but not to TNF-induced apoptosis (Fig. 4C) . Thus, Xbp1 genetic deficiency results in specific protection from the intrinsic pathway of apoptosis.
The resistance of Xbp1-deficient cells to apoptosis results from the activation of IRE1a Xbp1 deficiency results in activation of its upstream enzyme IRE1a, which degrades specific cytosolic RNA targets (16, 17) . Although they cannot make XBP1s protein, Xbp1-deficient cells transcribe mRNA that contains the IRE1a cleavage sites. Consistent with previous reports, we observed IRE1a activation in Xbp1-deficient cells, indicated by Xbp1 mRNA splicing ( fig. S7A ). The magnitude of IRE1a activation in Xbp1-deficient cells was not as robust as the response to canonical UPR stimulation with thapsigargin, nor were classical RIDD substrates diminished ( fig. S7B) , consistent with other studies (39).
To determine whether IRE1a was involved in resistance to apoptosis, we knocked down Ire1a with siRNA ( fig. S7C) . As a functional control, Ire1a-specific siRNA efficiently prevented Xbp1 mRNA splicing ( fig. S7D ). IRE1a knockdown in Xbp1 −/− MEFs reversed resistance to VSV-induced cell death (Fig. 5A and fig. S7E ). Expression of human Cre − littermate (WT) mice in the presence of tamoxifen and treated with the indicated inducers of cell death as described in (A). Twenty-four hours later, viability was assessed by measuring MTS reduction. Data are means ± SD of three replicates and are representative of three experiments. *P < 0.05; **P < 0.001 compared to WT, unpaired t test.
IRE1a, which was resistant to mouse Ire1a-specific siRNA, prevented this reversal ( fig. S7F ). IRE1a knockdown alone was minimally cytotoxic but restored caspase-3 activation in Xbp1 −/− MEFs in response to staurosporine (Fig. 5B ) and sensitized these cells to staurosporineinduced cell death (Fig. 5C ). To determine whether the RNase activity of IRE1a mediated resistance to apoptosis, we treated Xbp1-deficient cells with the selective IRE1a nuclease inhibitor 4m8C (8-formyl-7-hydroxy-4-methylcoumarin) (40) . We found that 4m8C reversed the resistance of Xbp1-deficient cells to apoptosis both during infection with VSV and during treatment with staurosporine (Fig. 5D ). As a negative control, the structurally similar compound AMC (7-amino-4-methylcoumarin) had no effect at an equimolar concentration ( fig.  S2D ). These findings indicate that the RNase activity of IRE1a contributes to resistance to the intrinsic pathway of apoptosis observed in the setting of Xbp1 deficiency. We consistently observed Xbp1 mRNA splicing to a small extent in WT cells (fig. S7 , A and C), suggesting that IRE1a has some basal activity (41) , which could regulate apoptotic responses in WT cells. Consistent with this, IRE1a knockdown in WT MEFs was not toxic alone (Fig. 5 , B, C, and E) but sensitized cells to VSV-induced cell death and limited viral replication (Fig. 5, E and F) .
IRE1a targets the proapoptotic miRNA miR-125a
Studies of coding genes targeted by IRE1a for RIDD have not revealed obvious candidates to explain our observed IRE1a-mediated resistance to apoptosis (9, 42) . Thus, we focused on miRNAs, which are also targeted by RIDD (43) . To this end, we performed miRNA profiling of Xbp1-deficient cells and found four miRNAs that were decreased in abundance in Xbp1-deficient cells with active IRE1a (Fig. 6A) . The miRNA miR-125a was represented twice among these differentially expressed miRNAs. Quantitative polymerase chain reaction (PCR) analysis confirmed the decrease in miR-125a abundance in Xbp1-deficient cells, which was restored by reconstitution of the cells with plasmid-encoded Xbp1 (fig.  S8A ). The miRNA miR-125a sensitizes cells to apoptosis and is thought to negatively regulate antiapoptotic Bcl-2 family members, including B cell lymphoma-extra large (Bcl-xL) and myeloid cell leukemia 1 (Mcl-1) (44) (45) (46) . In accordance with decreased miR-125a, we found an increase in the abundances of antiapoptotic Bcl-xL and Mcl-1 proteins in Xbp1-deficient cells (Fig. 6B) XBP1D IRE1aD BMDMs were reduced compared to those in XBP1D cells, albeit not to the amount observed in the WT cells (Fig. 6B) . These results indicated that antiapoptotic Bcl-xL and Mcl-1 proteins were increased in abundance in Xbp1-deficient cells, in a manner largely dependent on IRE1a. Consistent with our observation of sensitization to apoptosis by IRE1a knockdown in WT cells (Fig. 5E ), IRE1aD cells had increased miR-125a abundance ( fig. S8B) . Inhibition of the RNase activity of IRE1a with the selective IRE1a nuclease inhibitor 4m8C was sufficient to increase the abundance of miR-125a ( fig. S8B ). Finally, we wished to examine the extent to which miR-125a degradation by IRE1a was responsible for the prosurvival phenotype of the Xbp1-deficient cells. Reconstitution of miR-125a with an miRNA mimetic was sufficient to restore caspase-3 activation in Xbp1 −/− MEFs in response to staurosporine (Fig. 6C) and to sensitize Xbp1-deficient cells to the intrinsic pathway of apoptosis (Fig. 6D and fig. S8C ). Reconstitution with miR-125a also reversed the resistance of Xbp1
MEFs to VSV-induced cell death (Fig. 6E) . Finally, neutralizing miR125a in WT cells with an miRNA hairpin inhibitor resulted in an antiapoptotic state resembling that observed in Xbp1-deficient cells ( fig. S8D ). Together, these findings suggest that the IRE1a-dependent decrease in miR-125a abundance contributes to the resistance to apoptosis.
IRE1a activation during HCV infection mediates resistance to apoptosis
Some viruses encode genes that promote IRE1a activation. HCV NS4B activates IRE1a (18) , and IRE1a activation is also seen in HCV-infected cells (47) . Curiously, in cells expressing NS4B, IRE1a splices Xbp1 mRNA, but XBP1 targets are not transcribed (18) , suggesting that the virus uses IRE1a for another reason. Furthermore, HCV is suggested to cause resistance to the intrinsic pathway of apoptosis (48, 49) , although the mechanism of this effect remains unknown. Consistent with previous reports (18), we detected IRE1a activation as indicated by spliced XBP1 mRNA in cells transiently transfected with a plasmid encoding NS4B (Fig. 7A) . The abundance of miR-125a was decreased ( fig. S8E) , and NS4B expression induced the IRE1a-dependent resistance to staurosporine (Fig. 7, B and C). We infected Huh-7.5 human hepatoma cells with trans-packaged HCV replicons encoding Gaussia luciferase (Gluc), which enabled us to quantitate HCV replication over time (50) . IRE1a inhibition alone was not cytotoxic, but it sensitized HCV-infected cells to death (Fig. 7D) . Furthermore, inhibition of IRE1a decreased the secretion of virally encoded luciferase, a marker of viral replication (Fig. 7E) . These findings suggest that IRE1a activation during HCV infection may promote viral replication by inhibiting the death of the infected cells. To determine whether these findings extended to human HCV infection, we quantified spliced XBP1 mRNA in the human liver tissue of patients infected with HCV. We detected HCV-associated IRE1a activation, as indicated by an increase in spliced XBP1 mRNA abundance in liver tissue from HCV-infected patients compared to that in the liver tissue of HCV-negative controls (Fig.  7F) . In addition to IRE1a activation, HCV-infected patients also exhibited statistically significantly reduced miR-125a abundance (Fig. 7G) , suggesting that IRE1a activation during human HCV infection may confer resistance to apoptosis.
DISCUSSION
Here, we examined the IRE1a-XBP1 branch of the UPR in innate antiviral defense. We uncovered an unexpected role for Xbp1 and IRE1a in modulating susceptibility to the intrinsic pathway of apoptosis, which is induced during VSV and HSV infection and plays a critical role in limiting viral replication. Xbp1 −/− MEFs were protected from virally induced cell death and, as a consequence, sustained more viral replication despite an increased IFN response compared to that of WT cells. In Xbp1
−/− cells with active IRE1a, the abundance of the proapoptotic miRNA miR-125a was decreased, conferring resistance to the intrinsic apoptotic pathway. IRE1a activation by HCV NS4B in WT cells also conferred resistance to apoptosis and promoted viral replication. Therefore, Xbp1-deficient cells with active IRE1a gained apoptosis resistance, which suggests that IRE1a Secretion of virally encoded luciferase was measured 24 and 48 hours after infection (E). Data are means ± SD of three replicates and are representative of two experiments. (F and G) RNA was isolated from the liver tissue of HCV-infected patients (n = 11) and HCV-negative controls (n = 6). Expression of spliced XBP1 and miR-125a (relative to an internal control) was determined by quantitative RT-PCR. Data are means ± SEM. *P < 0.05; **P < 0.01, unpaired t test. ***P < 0.01, Mann-Whitney test.
knockdown or inhibition is a model for the loss of apoptosis resistance. Finally, we observed IRE1a activation and substantially less miR125a abundance in liver biopsies from HCV-infected patients, suggesting the in vivo relevance of the survival strategy used by HCV. These results highlight a previously unappreciated role of the IRE1a-XBP1 axis in the regulation of apoptosis and its consequences in viral susceptibility. Previous studies showed that after the engagement of TLRs and RLRs, XBP1 plays an important role in enhancing cytokine and IFN production in macrophages and dendritic cells (11) (12) (13) . Given the observation that transfection with poly(I:C) induced less IFN production in Xbp1 −/− MEFs compared to that in WT MEFs, our results are consistent with these previous findings that Xbp1 promotes RLR signaling for IFN production in MEFs. However, despite this impairment in IFN production downstream of RLRs, infected Xbp1-deficient MEFs produced large amounts of IFN. We speculate that the enhanced IFN response observed in Xbp1 −/− MEFs may result from both prolonged cellular survival and an accumulation of viral PAMPs. Apoptotic caspases can cleave and inactivate signaling proteins important for the IFN response, suggesting that the apoptotic process directly antagonizes the IFN response (51) (52) (53) (54) . In addition, IRE1a can cleave host RNA for RLR stimulation (15) . Therefore, our results highlight a distinct consequence of IRE1a activation, whereby Xbp1 deficiency results in a robust prosurvival response, leading to prolonged RLR stimulation that mitigates impairment in RLR signaling to generate enhanced IFN responses. The prosurvival signals induced through IRE1a activation are so dominant that they overcome ISG-mediated antiviral functions and enable virus replication.
In addition to protection from virus-induced death, we found that Xbp1 deficiency conferred resistance to the intrinsic pathway of apoptosis stimulated by various chemical inducers. IRE1a activation in Xbp1-deficient cells contributed to this apoptosis resistance because siRNA-mediated knockdown of Ire1a expression or inhibition of IRE1a nuclease function rendered the Xbp1-deficient cells susceptible to apoptosis. RIDD targets both coding and noncoding RNAs, including miRNAs (42) . We found that IRE1a reduced the amount of miR125a, leading to the enhanced expression of its target genes. The targets include genes encoding prosurvival members of the Bcl-2 family (44) (45) (46) . miRNA controls target genes at the transcriptional and translational levels (55) . We found that the prosurvival proteins Bcl-xL and Mcl-1 were present in increased amounts. The biological targets and functions of the other miRNAs identified in this study, namely miR-1224 and miR-804, have not yet been well described. The relevance of these other miRNAs in IRE1a-dependent phenotypes will be investigated in future studies.
Our study revealed an unexpected role for IRE1a in controlling apoptosis. Many studies of the UPR have been performed with high concentrations of pharmacological inducers of ER stress, such as tunicamycin and thapsigargin, which inevitably lead to cell death. In these experimental settings of irremediable ER stress, various mechanisms have been proposed for inducing apoptosis (56) . The net effect of IRE1a activity in promoting cell death compared to cell survival has been controversial, with some studies suggesting that IRE1a promotes cell survival (57) (58) (59) , and others suggesting that IRE1a promotes cell death (60) (61) (62) . Specifically, IRE1a was proposed to induce apoptosis by degrading miRNAs that lead to increased caspase-2 abundance (60), although there are conflicting data challenging this observation (63) . IRE1a has been linked to apoptosis in cells irreversibly damaged by the activation of the JNK (c-Jun N-terminal kinase)-ASK1 (apoptosis signal-regulating kinase 1) pathway (64, 65) . IRE1a appears to have opposing roles in regulating apoptosis: prosurvival in the absence of irreversible UPR but proapoptotic under irreversible UPR. This double-edged nature of IRE1a may be important to consider for the use of IRE1a inhibitors in the treatment of various human diseases (66) .
We speculate that IRE1a may represent an ancient form of cell protection that has been subverted by some viruses for their own replicative advantage. HCV and other members of the Flaviviridae family induce ER stress and activate IRE1a. Our results suggest that HCV NS4B induces IRE1a-dependent protection from apoptosis, which may favor the development of chronic infection and hepatocellular carcinoma. In the setting of avian coronavirus infection, IRE1a also promotes cell survival in association with JNK and Akt regulation (67) . Influenza virus induces only the IRE1a arm of the UPR (not ATF6 or PERK), and inhibitors of IRE1a reduce viral replication (68) . Therefore, our findings predict that the IRE1a-RIDD pathway could be exploited as a novel target of intervention against viral infections.
MATERIALS AND METHODS
Cells and viruses
Xbp1
+/+ and Xbp1 −/− MEFs were gifts from L. H. Glimcher (Weill Cornell Medical College, New York, NY). H1-HeLa cells stably overexpressing the antiapoptotic protein BCL2 have been previously described (69) . MEFs and H1-HeLa cells were propagated in high-glucose Dulbecco's modified Eagle's medium (DMEM) (Gibco) and supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% Hepes, and penicillin (100 U/ml) and streptomycin (100 mg/ml) (Gibco). Huh-7.5 cells were propagated in high-glucose DMEM with 10% heat-inactivated FBS and 1 mM nonessential amino acids (Invitrogen). (70) [RIKEN BioResource Center (BRC), Japan], and CAGGCre-ER TM (the Jackson Laboratory) mice were bred in the Yale animal facility. All procedures performed in this study complied with the federal guidelines and institutional policies set by Yale Animal Care and Use Committee. BMDMs were prepared from 6-to 12-week-old male and female mice according to a previously described method (71) and cultured in 0.2 mM 4-hydroxytamoxifen (Sigma) during days 2 to 4 of differentiation to induce Cre-mediated recombination. The following genotype combinations of BMDMs were treated with tamoxifen to generate the cells described in Fig Infection and stimulation of cells Cells were incubated for 1 hour with VSV or HSV-1 in serum-free medium or pseudotyped virus in phosphate-buffered saline 0.1% bovine serum albumin, and then the inoculum was removed, and incubation continued in complete medium. Cells were incubated for 4 hours with trans-packaged HCV, and then the inoculum was removed, and incubation continued in complete medium containing 60 mM IRE1 Inhibitor II (Calbiochem). zVAD (Invivogen) was added at 20 to 100 mM after removal of the viral inoculum. Poly(I:C) (1 mg/ml) was delivered complexed to Lipofectamine 2000 (Invitrogen). Cells were treated with 0.1 to 1 mM staurosporine (Enzo Life Sciences), 1 mM gliotoxin (Sigma), 10 mM ABT-737 (Santa Cruz Biotechnology), TNF (50 ng/ml) + cycloheximide (0.1 mg/ml) (Abcam), antimouse CD95 (2 mg/ml) (BD Pharmingen), Fas-activating antibody + cycloheximide (0.1 mg/ml), tunicamycin (10 to 100 mg/ml) (Sigma), 1 mM thapsigargin (Calbiochem), or cycloheximide (100 mg/ml) (high-dose CHX). Cells were treated with the IRE1 inhibitor 4m8C (Calbiochem) or the structurally similar compound AMC (Sigma) at 25 mM for 3 days before infection or apoptosis induction or 40 mM IRE1 Inhibitor II (Calbiochem) for 24 hours before apoptosis induction.
Plasmids pFLAG.XBP1u.CMV2 (Addgene plasmid #21832, from D. Ron) (73), the empty vector control c-Flag pcDNA3 (Addgene plasmid #20011, from S. Smale) (74), hIRE1a.pcD (Addgene plasmid #21892, from R. Kaufman), and hIRE1a wt (Addgene plasmid #20744, from F. Urano) (75) were used. MEFs were transfected using TransIT-2020 (Mirus Bio). HCV NS4B was expressed with an authentic N-terminal Ala residue by fusing a human ubiquitin gene to a codon-optimized NS4B gene (76): Ubiquitin was amplified by using primers YO-0905 (TTA ATT AAC GAG GAT CCC GCC ACC ATG CAG ATC TTC GTG AAG AC) and YO-0928 (TCG ATC AGG GCT GCT CTG CTG GCT CCA CCG CGG AGA CGC AGC ACC); codon-optimized NS4B was amplified by using primers YO-0927 (GGT GCT GCG TCT CCG CGG TGG AGC CAG CAG AGC AGC CCT GAT CGA) and YO-0931 (GTT TAA ACT TAA CAA GGG ATG GGG CAG TCC T). Ubi-NS4B was then assembled in secondary PCRs with primers YO-0905 and YO-0931, cloned into pCR2.1 (Invitrogen) for sequencing, and then subcloned into pIRES2-EGFP (Clontech) by using the common Sac I and Pst I restriction sites. H1-HeLa cells were transfected using TransIT-HeLa (Mirus Bio).
Expression analysis RNA isolated using the RNeasy kit (Qiagen) was used to synthesize complementary DNA (cDNA) using the iScript cDNA Synthesis Kit (Bio-Rad), and quantitative PCR was performed on a Stratagene Mx3000P or Bio-Rad CFX Connect using SYBR Green (Bio-Rad) with the following primers (all primers listed in the 5′ to 3′ orientation): Ifna4, CTG CTA CTT GGA ATG CAA CTC (forward) and CAG TCT TGC CAG CAA GTT GG (reverse); Ifnb1, GCA CTG GGT GGA ATG AGA CTA TTG (forward) and TTC TGA GGC ATC AAC TGA CAG GTC (reverse); Mx1, AGT CCT TTC CAC AGG CAG AA (forward) and CAT TGA GAG AAA CTC ACC TAA GAA C (reverse); Xbp1s, GAG TCC GCA GCA GGT (forward) and GTG TCA GAG TCC ATG GGA (reverse); Hspa5 (Bip), TCA TCG GAC GCA CTT GGA (forward) and CAA CCA CCT TGA ATG GCA AGA (reverse); Chop, GTC CCT AGC TTG GCT GAC AGA (forward) and TGG AGA GCG AGG GCT TTG (reverse); Blos1, CAA GGA GCT GCA GGA GAA GA (forward) and GCC TGG TTG AAG TTC TCC AC (reverse); Pdgfrb, AAC CCC CTT ACA GCT GTC CT (forward) and TAA TCC CGT CAG CAT CTT CC (reverse); and human spliced XBP1, TGC TGA GTC CGC AGC AGG TG (forward) and GCT GGC AGG CTC TGG GGA AG (reverse). For analysis of Xbp1-splicing, primers flanking the spliced sequences in Xbp1 mRNA [ACA CGC TTG GGA ATG GAC AC (forward) and CCA TGG GAA GAT GTT CTG GG (reverse)] were used for PCR amplification, and products were separated by electrophoresis through a 3% agarose gel and visualized by ethidium bromide staining.
miRNA expression analysis RNA isolated using the miRNeasy Mini Kit (Qiagen) was subjected to miRNA profiling using the nCounter mouse miRNA expression assay version 1.5 (NanoString) according to the manufacturer's protocol. Data were analyzed by using the nSolver software with normalization to the geometric mean of the top 100 miRNAs as recommended by the manufacturer. Quantitative RT-PCR with the miRCURY Universal RT microRNA qPCR system (Exiqon) was used to measure miR-125a-5p. Expression was calculated relative to the manufacturer's suggested endogenous control (miR-103a-3p), with equivalent results also obtained relative to miR-16-5p.
Assessment of cell death
Cells were stained with the LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Molecular Probes) and analyzed by flow cytometry on a BD FACSCalibur or BD LSRFortessa. Viability was also assessed by measuring MTS reduction using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Cells were stained with the Caspase-3, Active Form, Apoptosis Kit (BD Pharmingen) and analyzed by flow cytometry on a BD FACSCalibur. Caspase-3/7 activity was measured using the SensoLyte Homogeneous Rh110 Caspase-3/7 Assay Kit (AnaSpec).
Western blotting
Cell pellets were lysed in SDS sample buffer (Cell Signaling Technology). Proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes, and incubated with antibodies against Mcl-1 (BioLegend, 613601), Bcl-xL (Cell Signaling Technology, 54H6), or b-actin (Cell Signaling Technology, 13E5).
Intracellular staining
Cells were fixed in Cytofix/Cytoperm solution (BD) on ice, washed with Perm/Wash buffer (BD), and stained with DyLight 550-conjugated antibody against Beclin 1 (Novus Biologicals, NB110-87318R) or an equal concentration of isotype control antibody. Washed cells were analyzed by flow cytometry on a BD LSRFortessa flow cytometer.
siRNA, miR mimetics, and inhibitors Gene-specific siGENOME siRNA or siGENOME Non-Targeting siRNA #4 (which targets firefly luciferase mRNA and has at least four mismatches to all mouse genes) obtained from Dharmacon (Thermo Fisher Scientific) was delivered complexed to Lipofectamine RNAiMAX (Invitrogen). After incubation for 48 hours, cells were replated at equal density before infection or apoptosis induction. miR mimetics, miRI-DIAN microRNA hairpin inhibitor negative control #1, and miRIDIAN miR-125a hairpin inhibitor were obtained from Dharmacon (Thermo Fisher Scientific) and delivered complexed to Lipofectamine RNAiMAX (Invitrogen).
Luciferase assay
Conditioned cell culture medium was collected at 24 or 48 hours after infection, clarified by centrifugation, mixed with 1 / 4 volume 5× lysis buffer (New England Biolabs), and assayed for luciferase activity (New England Biolabs).
Liver specimens Liver samples from percutaneous biopsies of liver transplant recipients chronically infected with HCV or from HCV-negative control liver transplant recipients were obtained with the approval of the University of Washington Institutional Review Board. Tissue was archived in RNAlater and stored at −80°C. RNA was isolated using the miRNeasy Mini Kit (Qiagen).
Statistical analyses
Sample size was chosen according to previous experience in similar experiments; all samples were included in analysis. The unpaired Student's t test or the Mann-Whitney test was used for comparisons between two groups. P values of less than 0.05 were considered statistically significant.
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